Since 1993 the US Armed Forces Institute of Pathology has collected DNA samples, which are used to augment standard procedures for remains identification. These samples are collected from both active duty personnel and selected high-risk reserve personnel. As of 1995 the repository held 1.15 million samples.
yeast emphasize the potential power of genetic analysis to shed light on both normal as well as abnormal biology. Thus, obtaining genetic information on populations of normal subjects is also of great interest to the scientific community.
In order to study these questions in human populations, extremely large sample sizes are required to detect the generally modest and interacting effects of individual genes. In addition, each individual needs to provide detailed information about environmental exposures as well as the presence of disease or other phenotypes of interest. Ideally, one should obtain such information before the development of disease in order to more reliably document exposures. In addition, by enrolling subjects before the development of disease, one can study a large number of different disease outcomes using one study population. T he last decade has witnessed remarkable success in defining the genetic basis of a large number of single gene disorders, as well as the identification of certain high penetrance genes that underlie a proportion of more common illnesses, such as BRCA-1 in breast cancer. However, the promise of genetic analysis is now widely acknowledged to extend into the understanding of almost all common human diseases, including cardiovascular disease, autoimmunity, neurodegenerative disorders and most forms of cancer. In this context, it is likely that large numbers of different genes contribute to disease risk, in different combinations, and probably only in the setting of certain environmental risk factors such as diet, smoking, chemical exposures or lack of physical activity, to name only a few. The recent identification of genes controlling longevity in
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This approach, known as a cohort study, comprises the study design of the New York Cancer Project. The New York Cancer Project was launched in November of 1998 with a $12 million pilot grant from the City of New York. The goal of this project is to enroll up to 300,000 New Yorkers in a long term cohort study of cancer risk, with an emphasis on gene-gene and gene environment interactions. This ambitious project was initiated by the Academic Medicine Development Corporation (AMDeC), in collaboration with New York area researchers and institutions. AMDeC is a unique non-profit organization whose mission is to support biomedical research in New York State through collaboration with 36 New York academic health centers, research institutions and medical schools. AMDeC's President, Dr. Maria Mitchell, has been instrumental in fostering a number initiatives to increase the ability of these institutions to pursue large collaborative projects, many of which are focused on human genetics and functional genomics. The New York Cancer Project itself is headed by Dr. Tom Rohan, Chairman of the Department of Epidemiology at the Albert Einstein College of Medicine.
In addition to the recruitment and characterization of study subjects, a major challenge for large population studies is the proper preparation and storage of biological materials, particularly DNA and RNA, in a biorepository. Broadly, a biorepository is a biological specimen bank which will store one or more types of biological specimens under conditions which permit rapid retrieval and optimum stability. Robotic systems are highly desirable in this context, in order to eliminate the errors associated with human handling of vast numbers of visually identical samples, and to provide continuous monitoring of sample quality and storage conditions.
The need for such biorepository facilities is clear when one considers the increasing number of large scale projects that are underway which require storage of DNA and other biological materials (see boxed inset). The New York Cancer Project has approached this problem by developing a novel robotic system in collaboration with the Medical Automation Research Center (MARC) at the University of Virginia. The overall design of this system has been a product of over a year of planning by the authors. Robin A Felder, Ph.D., is the Director of MARC, and Peter K. Gregersen, M.D., serves as the Director of the NYCP Biorepository. Other participants in the system development include Robert Lundsten, Assistant Director of the NYCP Biorepository, Sean Graves, Ph.D., Director of MARC's robotics division, and Theodore E. Mifflin, Ph.D., Director of MARC's molecular automation division.
The NYCP Biorepository facility is located at the North Shore University Hospital in Manhasset, New York. This facility currently receives 50-100 blood specimens per day from NYCP recruitment sites. After a streamlined process of manual sample preparation, DNA, plasma and RNA derived from these samples are handled robotically for specimen aliquoting and storage. Extracted DNA, plasma and sources of RNA will be automatically quantitated by the robotic system so that aliquots of similar concentration and volume may be stored in individually retrievable aliquots for studies. For short to intermediate term storage,
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Sealer DNA samples will be placed in an automated refrigerator (Mol Bank, Gira, France) for convenient access by investigators. In addition, samples will be archived for long term storage systems (Revco Technologies Inc., Asheville, NC) to assure availability of specimens for many years into the future. It is anticipated utilization will grow substantially in the later years, when longitudinal follow up of the study population reveals the emergence of diseases and phenotypes of interest.
One of the key features of the NYCP Biorepository is the ability to provide biorepository personnel with rapid random access to hundreds of thousands of DNA samples stored in the Molbank. These samples can be aliquoted and supplied in 96 well formats for PCR analysis by the system itself, or by collaborating investigators. Since large numbers of SNPs and other polymorphisms are being defined in the human genome, it is likely that tens or even hundreds of thousands of analyses may be done on some samples. The relatively large amount of DNA collected by the NYCP on each individual (>1mg), and the low requirements for PCR based analyses (1 ng or less), make this feasible.
Additional information about the New York Cancer Project and AMDeC can be found at www.amdec.org. n ============================================== The cover image is a computer-generated illustration that includes equipment from a variety of laboratory automation companies. The different automation systems represented are the Genesis, Spectrafluor and Molbank from Tecan AG; the Carousel, Regripper, and Robot Arm (with controller), from CRS; the OmniGrid from GeneMachines; a balance from Sartorius and a Microplate Sealer from ABgene.
The cover image was generated by Elle Kovarikova, Medical Automation Research Center (MARC), University of Virginia.
This section compiled by Catherine Piche, University of Virginia DNA Sciences (Mountain View, CA) <http://www.DNA.com> DNA Science's Gene Trust Project is a repository of patient specimens and health information. All participants in the repository are volunteers who register on DNA Science's website, answer questions regarding their medical histories, and arrange a time and place for DNA Sciences to obtain a blood sample.
